Plasmodium vivax

Plasmodium vivax
Name	Plasmodium vivax
Domain	Eukaryota
Kingdom	Chromista
Phylum	Apicomplexa
Class	Aconoidasida
Order	Haemospororida
Family	Plasmodiidae
Genus	Plasmodium
Species	P. vivax
Binomial	Plasmodium vivax
Binomial authority	(Laveran, 1890)

Plasmodium vivax is a protozoan parasite and a major causative agent of human malaria. It is the most geographically widespread of the human-infecting Plasmodium species, responsible for millions of clinical cases annually, particularly in Asia and the Americas. The parasite is transmitted through the bite of an infected female Anopheles mosquito and is characterized by its ability to form dormant liver-stage hypnozoites, which can cause relapses months or years after the initial infection. Its complex life cycle and unique biological features present significant challenges for global eradication efforts.

Biology and life cycle

The life cycle involves both a human host and an Anopheles mosquito vector. During a blood meal, sporozoites from the mosquito's salivary glands enter the human bloodstream and travel to the liver, where they invade hepatocytes. Unlike Plasmodium falciparum, some sporozoites develop into dormant hypnozoites, while others undergo asexual replication (exo-erythrocytic schizogony) to produce merozoites. These merozoites are released into the bloodstream, where they invade reticulocytes (young red blood cells), initiating the erythrocytic cycle. Within the red blood cell, the parasite progresses through ring, trophozoite, and schizont stages, eventually rupturing the cell to release new merozoites. Some merozoites differentiate into sexual forms (gametocytes), which, when taken up by another Anopheles during a blood meal, undergo fertilization in the mosquito's midgut to form an ookinete. This penetrates the gut wall, forms an oocyst, and ultimately produces sporozoites that migrate to the salivary glands, completing the cycle.

Epidemiology and distribution

It is endemic across vast tropical and subtropical regions, with significant transmission in parts of South Asia, Southeast Asia, the Western Pacific, Latin America, and the Horn of Africa. Historically, its range extended into temperate zones, including Southern Europe and North America. The World Health Organization estimates it causes approximately 4.5 million clinical cases each year. Transmission intensity is influenced by factors such as the presence of competent Anopheles vectors like Anopheles stephensi and Anopheles darlingi, climate conditions, and human migration patterns. Notably, the parasite's ability to cause relapses from hypnozoites contributes to sustained transmission in endemic areas and complicates efforts by organizations like the Centers for Disease Control and Prevention to achieve elimination.

Clinical features and diagnosis

Infection typically causes a febrile illness characterized by paroxysms of fever, chills, and sweats occurring every 48 hours, known as tertian periodicity. Other common symptoms include headache, malaise, nausea, and anemia due to the preferential invasion of reticulocytes. While often considered less severe than Plasmodium falciparum malaria, it can cause severe and fatal complications, including splenic rupture, severe anemia, and acute respiratory distress syndrome. Diagnosis is primarily made by microscopic examination of Giemsa-stained blood smears, where the parasite's enlarged, amoeboid trophozoites and Schüffner's stippling in infected red cells are diagnostic. Rapid diagnostic tests targeting specific antigens and molecular techniques like polymerase chain reaction are also used, particularly for detecting low-level parasitemia.

Treatment and drug resistance

First-line treatment for the blood-stage infection has historically relied on chloroquine, often combined with primaquine or tafenoquine to target the dormant hypnozoites in the liver and achieve a radical cure. However, widespread chloroquine resistance has been confirmed in regions such as Indonesia, Papua New Guinea, and parts of the Amazon Basin, necessitating the use of alternative artemisinin-based combination therapies like artesunate-pyronaridine or artemether-lumefantrine. Resistance to primaquine is not well-defined but is a concern. The World Health Organization now recommends universal testing for glucose-6-phosphate dehydrogenase deficiency prior to administering primaquine or tafenoquine due to the risk of severe hemolysis in deficient individuals.

Prevention and control

Control strategies align with general malaria prevention and include the use of long-lasting insecticidal nets, indoor residual spraying with insecticides like DDT or pyrethroids, and chemoprevention in high-risk groups such as pregnant women. In endemic areas, mass drug administration campaigns with primaquine have been piloted to reduce the hypnozoite reservoir. Travelers to endemic regions are advised to use chemoprophylaxis, with drugs like atovaquone-proguanil or doxycycline being effective. Research into vaccine development is ongoing, with candidates like PvDBP targeting the Duffy binding protein involved in red cell invasion. Environmental management and surveillance by bodies like the Pan American Health Organization are critical components of regional elimination programs.

History and research

The parasite was first described by Charles Louis Alphonse Laveran and later named by William H. Welch in 1897. Its unique biological features, such as the hypnozoite stage, were elucidated through work by researchers like Wesley C. Ketchum and Robert S. Desowitz. A landmark discovery was the identification of the Duffy antigen as a critical receptor for red cell invasion; many individuals of West African descent who lack this antigen are naturally resistant. Contemporary research, supported by institutions like the National Institutes of Health and the Wellcome Trust, focuses on genomics, drug discovery targeting hypnozoites, and understanding the mechanisms of relapse and transmission. The complete genome sequence, published in 2008, has accelerated the search for new drug and vaccine targets.

Category:Apicomplexa Category:Parasites Category:Malaria